Fulvestrant for hormone-sensitive metastatic breast cancer
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Fulvestrant for Hormone-sensitive Metastatic Breast Cancer." Evidence-Based Medicine Guidelines, John Wiley & Sons, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/1305171/all/Fulvestrant_for_hormone_sensitive_metastatic_breast_cancer.
Fulvestrant for hormone-sensitive metastatic breast cancer. Evidence-Based Medicine Guidelines. John Wiley & Sons; 2025. https://evidence.unboundmedicine.com/evidence/view/EBMG/1305171/all/Fulvestrant_for_hormone_sensitive_metastatic_breast_cancer. Accessed March 28, 2025.
Fulvestrant for hormone-sensitive metastatic breast cancer. (2025). In Evidence-Based Medicine Guidelines. John Wiley & Sons. https://evidence.unboundmedicine.com/evidence/view/EBMG/1305171/all/Fulvestrant_for_hormone_sensitive_metastatic_breast_cancer
Fulvestrant for Hormone-sensitive Metastatic Breast Cancer [Internet]. In: Evidence-Based Medicine Guidelines. John Wiley & Sons; 2025. [cited 2025 March 28]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/1305171/all/Fulvestrant_for_hormone_sensitive_metastatic_breast_cancer.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Fulvestrant for hormone-sensitive metastatic breast cancer
ID - 1305171
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/1305171/all/Fulvestrant_for_hormone_sensitive_metastatic_breast_cancer
PB - John Wiley & Sons
DB - Evidence Central
DP - Unbound Medicine
ER -